African Journal of
Biotechnology

  • Abbreviation: Afr. J. Biotechnol.
  • Language: English
  • ISSN: 1684-5315
  • DOI: 10.5897/AJB
  • Start Year: 2002
  • Published Articles: 12401

Full Length Research Paper

Qianliening capsule treats benign prostatic hyperplasia (BPH) by down-regulating the expression of PCNA, CyclinD1 and CDK4

  Xiaoyong Zhong1, Jiumao Lin1,2, Jianheng Zhou3, Wei Xu4, Zhenfeng Hong1* and Jun Peng1,2  
  1Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, 1 Huatuo Road, Minhou Shangjie, Fuzhou, Fujian 350108, China. 2Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, 1 Huatuo Road, Minhou Shangjie, Fuzhou, Fujian 350108, China. 3Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, 1 Huatuo Road, Minhou Shangjie, Fuzhou, Fujian 350108, China. 4Department of Pharmacology, Fujian University of Traditional Chinese Medicine, 1 Huatuo Road, Minhou Shangjie, Fuzhou, Fujian 350108, China.
Email: [email protected]

  •  Accepted: 08 March 2012
  •  Published: 12 April 2012

Abstract

 

Benign prostatic hyperplasia (BPH) is characterized by abnormal proliferation of epithelial and stromal cells in prostatic tissue, which is closely correlated with increased expression of PCNA, CyclinD1 and CDK4. Therefore, inhibition of cell proliferation by suppressing the expression of the above genes is a promising strategy in the development of novel anti-BPH therapies. The aim of this study was to investigate the effect of Qianliening capsule (QC), a traditional Chinese formulation that has been shown to be clinically effective in the treatment of BPH, on the expression of PCNA, CyclinD1 and CDK4 in prostatic tissues of BPH rats. Male Sprage-Dawley (SD) rats were castrated and subcutaneously injected with testosterone propionate to generate BPH model. Meanwhile, BPH rats were orally treated with QC, or with finasteride that was used as a positive control drug.Treatment with QC or finasteride significantly reduced the PI (Prostate Index, PI =prostate wet weight / body weight × 100%) in BPH rats (P<0.05). In addition, QC orfinasteride treatment significantly inhibited model construction-induced upregulation of expression of PCNA, CyclinD1 and CDK4 in prostatic tissues of BPH rats (P<0.05). Our findings for the first time demonstrated that QC can obviously reduce the PI, the expression of PCNA, CyclinD1 and CDK4 in the prostatic tissues of BPH rats, which may in part explain its anti-BPH activity.

 

Key words: Qianliening capsule, benign prostatic hyperplasia, cell proliferation, PCNA, CyclinD1, CDK4.

Abbreviation

Abbreviations: QC, Qianliening capsule; BPH, benign prostatic hyperplasia; PI, prostatic index; DHT, 5-dihihydrotestosterone; LUTS, lower urinary tract symptoms